Immunomodulating functions of recombinant ovine interferon tau: Potential for therapy in mulitple sclerosis and autoimmune disorders

Multiple Sclerosis

Volumn 4, Issue 2, 1998, Pages 63-69

  Khan, O A ^a,b   Jiang, H ^a   Subramaniam, P S ^c   Johnson, H M ^c   Dhib Jalbut, S S ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Autoimmune disorders; Experimental allergic encephalomylitis; Inteferons; Lymphotoxicity; Mulitple sclerosis; T cells

Indexed keywords

HLA ANTIGEN CLASS 2; RECOMBINANT INTERFERON; RECOMBINANT OVINE INTERFERON TAU; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; SIDE EFFECT; T LYMPHOCYTE;

EID: 0031956257     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859800400204     Document Type: Article

References (36)

1. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. (1995) The interferons: biological effects, mechanisms of action and use in multiple sclerosis. Ann Neurol 37: 7 - 15.
2. Van Thiel DH, et al. (1995) Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of Interferon alpha 2b therapy. J Hepatol 23: 503 - 508.
3. Stentella P, et al. (1996) Topic and systemic administration of natural alfa Interferon in the treatment of female and male HPV genital infections. Clin Exp Obs Gynecol 23: 29 - 36.
4. Lauta VM. (1995) Interferon and myeloma. Med Oncology 12: 63 - 69.
5. Thiele J, et al. (1996) Effect of interferon therapy on bone marrow morphology in chronic myeloid leukemia: a cytochemical and immunohistochemical study of trephine biopsies. J IFN Cyto Res 16: 217 - 224.
6. IFNB Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655 - 661.
7. Jacobs LD, et al. (1996) Intramuscular Interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39: 285 - 294.
8. Durelli L, et al. (1994) Chronic systemic high-dose recombinant Interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and gamma production in relapsing-remitting multiple sclerosis. Neurology 44: 406 - 413.
9. Durelli L, et al. (1996) Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: Disease activity resumes after stopping treatment. Neurology 47: 123 - 129.
10. Bazer FW, Johnson HM. (1991) Type I conceptus interferon: maternal recognition of pregnancy signals and potential therapeutic agents. Am J Reprod Immunol 26: 19 - 22.
11. Johnson HM, Bazer FW, Szente BE, Jarpe MA. (1994) How interferons fight disease. Sci Am 270: 68 - 75.
12. Imakawa K, et al. (1987) Interferon-like sequence of ovine trophoblast protein secreted by embryonic trophoectoderm. Nature 330: 377 - 379.
13. Pontzer CH, et al. (1988) Antiviral activity of the pregnancy recognition hormone ovine trophoblast protein-1. Biochem Biophys Res Commun 152: 801 - 807.
14. Soos JM, Johnson HM. (1995) Type I interferon inhibition of superantigen stimulation: implications for treatment of superantigen-associated disease. J IFN Cyto Res 15: 39 - 45.
15. Soos JM, et al. (1995) The IFN pregnancy recognition hormone IFN-τ blocks both development and super-antigen reactivation of experimental allergic encephalo-myelitis without associated toxicity. J Immunol 155: 2747 - 2753.
16. Schiffenbauer J, et al. (1993) Staphylococcal enterotoxins can recativate experimental allergic encephalomyelitis. Proc Natl Acad Sci 90: 8543 - 8546.
17. Soos JM, et al. (1997) Oral feeding of Interferon r can prevent the acute and chronic relapsing forms of experimental allergic encephalomyelitis. J Neuroimmunol 75: 43 - 50.
18. Chaouat G, et al. (1995) IL-10 prevents naturally occurring fetal loss in the CBA X DBA/2 mating combinations, and local defect in IL-10 production in this abortion-prone combination by in vivo injection of IFNR. J Immunol 154: 4261 - 4268.
19. Mujtaba MG, Soos JM, Johnson HM. (1997) CD4 Suppressor cells mediate interferon tau protection against experimental allergic encephalomyelitis. J Neuroimmunol 75: 35 - 42.
20. Yamabe T, et al. (1994) Cytokine-gene expression in measles-infected adult human glial cells. J Neuroimmunol 49: 171 - 179.
21. Van Heeke G, et al. (1996) High yield expression and secretion of the ovine pregnancy recognition hormone interferon-t by Pichia Pastoris. J IFN Cytokine Res 16: 119 - 126.
22. Pontzer CH, Bazer FW, Johnson HM. (1991) Antiproliferative activity of a pregnancy recognition formone, ovine trophoblast protein-1. Cancer Res 51: 5304 - 5307.
23. Dhib-Jalbut S, McFarlin DE, McFarland HF. (1989) Measles viruspolypeptide specificity of the cytotoxic T-lymphocyte response in mutliple sclerosis. J Neuroimmunol 21: 205 - 212.
24. Quesada JR. (1992) Toxicity and side effects of interferons. In: Baron S, Coppenhaver DH, Dianzani F, Fleischmann Jr. WR, Hughes Jr. TK, Kumpel GR, Niesel DW, Stanton GJ, Tyring SK, (eds.) Interferon: principles and medical applications. Galveston: The University of Texas Medical Branch Department of Microbiology, 427 - 432.
25. 1b on HLA expression and lymphoproliferation: a preclinical model for treatment of multiple sclerosis. J IFN Cyto Res 16: 195 - 200.
26. Jiang H, et al. (1995) Interferon β-1b reduces interferon γ-induced antigen presenting capacity of human glial and B cells. J Neuroimmunol 61: 17 - 25.
27. Joseph J, Knobler RL, D'Imperio C, Lublin FD. (1988) Down-regulation of interferon-,γ induced class II expression on human glioma cells by recombinant interferon-β: effects of dosage treatment schedule. J Neuroimmunol 20: 39 - 44.
28. Inaba K, et al. (1986) Contrasting effects of alphalbeta and gammainterferons on expression of macrophage la antigens. J Exp Med 163: 1030 - 1035.
29. Noronha A, Toscas A, Jensen MA. (1990). Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol 27: 207 - 210.
30. Leppert D, et al. (1996) Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 40: 846 - 852.
31. Stuve O, et al. (1996) Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 40: 853 - 863.
32. Knobler RL, et al. (1993) Systemic recombinant human interferon-β treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six year follow up. J IFN Res 13: 333 - 340.
33. Borden EC, et al. (1988) Clinical and biological effects of recombinant interferon beta administerred intravenously daily in phase I trial. J IFN Res 8: 357 - 366.
34. Drew PD, et al. (1993) Regulation of MHC class I and β2-microglobulin gene expression in human neuronal cells. J Immunol 150: 3300 - 3310.
35. Lu HT, et al. (1995) Interferon beta acts downstream of IFN-g induced class II tiansactivator MRNA accumulation to block MHC class II gene expression and requires the 48 kD DNA binding protein, ISGF3-γ. J Exp Med 182: 1517 - 1525.
36. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MSIMRI Analysis Group. (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 47: 889 - 894.